- Home
- / Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding
Stock Price
€136.4
2023-07-14
Market Capitalization
€239 M
2023-07-14
Revenue
CHF77.2 M
FY, 2025
Santhera Pharmaceuticals Holding Summary
Company Summary
- Overview
- Santhera Pharmaceuticals Holding is a specialty pharmaceutical company. It focuses on the discovery, preclinical and clinical development, and commercialization of pharmaceuticals in the area of neuromuscular and pulmonary conditions.
- Type
- Public
- Status
- Active
- Founded
- 2004
- HQ
- Pratteln, CH | view all locations
- Website
- https://www.santhera.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Otto Schwarz, Board Member
Thomas Meier, Founder, Chairman of the Board & Scientific Committee, Member of Compensation and Audit & Compliance Committees
Dario Eklund, Chief Executive Officer
Operating MetricsView all
New Pivotal Study Projects
1
FY, 2020
Phase I Trials Products
1
FY, 2020
Preclinical Phase Products
1
FY, 2020
LocationsView all
2 locations detected
Pratteln, Basel-Landschaft HQ
Switzerland
24 Hohenrainstrasse
Burlington, MA
United States
25 Corporate Dr #250
Santhera Pharmaceuticals Holding Financials
Summary Financials
- Revenue (FY, 2025)
- CHF77.2M
- Gross profit (FY, 2025)
- CHF21.1M
- Net income (FY, 2025)
- (CHF49.2M)
- Cash (FY, 2025)
- CHF22.4M
- EBIT (FY, 2025)
- (CHF37.6M)
- Enterprise value
- $267.3M